Table 1.
Clinical and pathological characteristics of patients and univariate analysis.
| Non_Relapsing Group n = 22 | Relapsing Group n = 26 | |||||||
|---|---|---|---|---|---|---|---|---|
| Cox Univariate Analysis | ||||||||
| Characteristics | n | % | n | % | RR | 95% CI | p-Value Likehood Ratio | |
| Gender | 0.76 | 0.34–1.69 | 0.51 | |||||
| Male | 15 | 68.2 | 16 | 61.5 | ||||
| Female | 7 | 31.8 | 10 | 38.5 | ||||
| Age (years) † | 0.5134 | 0.23–1.32 | 0.09302 | |||||
| Median | 15 | 10 | ||||||
| Range | 6–44 | 2–50 | ||||||
| St_Jude Stage †† | 1.405 | 0.51–3.84 | 0.49 | |||||
| I–II | 4 | 18.2 | 5 | 19.2 | ||||
| III–IV | 9 | 40.9 | 16 | 61.5 | ||||
| Ann Arbor Stage †† | 1.92 | 0.80–4.61 | 0.1266 | |||||
| I–II | 11 | 50.0 | 7 | 26.9 | ||||
| III–IV | 11 | 50.0 | 18 | 69.2 | ||||
| IPI score †† | 2.676 | 1.002–7.15 | 0.04183 | |||||
| 0–1 | 11 | 50.0 | 6 | 23.1 | ||||
| 2–3 | 5 | 22.7 | 12 | 46.2 | ||||
| LDH †† | 4.46 | 1.76–11.2 | 0.00422 | |||||
| <2 × ULN | 20 | 90.9 | 15 | 57.7 | ||||
| ≥2 × ULN | 1 | 4.5 | 7 | 26.9 | ||||
| Morphological subtype | 1.93 | 0.86–4.35 | 0.1018 | |||||
| Common Type | 13 | 59.1 | 9 | 34.6 | ||||
| SC/LH | 9 | 40.9 | 17 | 65.4 | ||||
| Fusion partner | 1.32 | 0.13–3.2 | 0.6934 | |||||
| NPM | 20 | 90.9 | 24 | 92.3 | ||||
| Others | 2 | 9.1 | 2 | 7.7 | ||||
| Peripheral lymph nodes †† | ||||||||
| No | 1 | 4.5 | 19 | 73.1 | ||||
| Yes | 11 | 50.0 | 0 | 0.0 | ||||
| Mediastinal involvement †† | 1.03 | 0.42–2.55 | 0.9411 | |||||
| No | 5 | 22.7 | 9 | 34.6 | ||||
| Yes | 7 | 31.8 | 10 | 38.5 | ||||
| Visceral involvement (spleen. liver or lung involvement) | 2.139 | 0.98–4.67 | 0.05414 | |||||
| No | 15 | 68.2 | 11 | 42.3 | ||||
| Yes | 7 | 31.8 | 15 | 57.7 | ||||
| Spleen involvement †† | ||||||||
| No | 18 | 81.8 | 20 | 76.9 | ||||
| Yes | 4 | 18.2 | 5 | 19.2 | ||||
| Liver involvement †† | ||||||||
| No | 20 | 90.9 | 19 | 73.1 | ||||
| Yes | 2 | 9.1 | 6 | 23.1 | ||||
| Lung involvement †† | ||||||||
| No | 18 | 81.8 | 14 | 53.8 | ||||
| Yes | 4 | 18.2 | 11 | 42.3 | ||||
| Other Visceral involvement †† | ||||||||
| No | 17 | 77.3 | 13 | 50.0 | ||||
| Yes | 5 | 22.7 | 13 | 50.0 | ||||
| Skin lesion †† | 1.11 | 0.46–2.69 | 0.8131 | |||||
| No | 18 | 81.8 | 17 | 65.4 | ||||
| Yes | 4 | 18.2 | 7 | 26.9 | ||||
| Clinical high risk group †† (spleen or/and liver or/and lung or/and mediastinal involvement or/and skin lesions) | 1.13 | 0.45–2.83 | 0.7843 | |||||
| No | 4 | 18.2 | 6 | 23.1 | ||||
| Yes | 12 | 54.5 | 20 | 76.9 | ||||
| Bone lesions †† | 0.96 | 0.33–2.79 | 0.9344 | |||||
| No | 19 | 86.4 | 21 | 80.8 | ||||
| Yes | 3 | 13.6 | 4 | 15.4 | ||||
| Bone marrow involvement †† | 1.062 | 0.41–2.83 | 0.9049 | |||||
| No | 17 | 77.3 | 21 | 80.8 | ||||
| Yes | 3 | 13.6 | 4 | 15.4 | ||||
| CNS involvement †† | 1.172 | 0.16–8.68 | 0.8793 | |||||
| No | 21 | 95.5 | 24 | 92.3 | ||||
| Yes | 1 | 4.5 | 1 | 3.8 | ||||
| Soft tissue mass †† | 2.53 | 0.594–10.78 | 0.2676 | |||||
| No | 21 | 95.5 | 23 | 88.5 | ||||
| Yes | 1 | 4.5 | 2 | 7.7 | ||||
| CD3 positivity †† | 0.73 | 0.27–1.97 | 0.53 | |||||
| Negative | 14 | 63.6 | 19 | 73.1 | ||||
| Positive | 6 | 27.3 | 5 | 19.2 | ||||
| MDD †† | 10.23 | 1.34–78.02 | 0.001735 | |||||
| Negative | 6 | 27.3 | 1 | 3.8 | ||||
| Positive | 3 | 13.6 | 17 | 65.4 | ||||
Abbreviations: IPI, international prognostic index; LDH, lactate dehydrogenase; Visceral involvement: lung, liver, spleen; CNS, central nervous system; MDD, minimal disseminated disease; PFS, progression free survival; CI, confidence interval; p, p value; RR, Relative Risk. †: groups defined by the following criteria: ≥ or < median age (12.5 years). ††: Missing Data: St-Jude Stage n = 14, Ann Arbor Stage n = 1, IPI score n = 14, LDH n = 5, peripheral lymph nodes n = 17, mediastinum n = 17, spleen n = 1, liver n = 1, lungs n = 1, other visceral involvement n = 1, skin lesions n = 2, clinical high risk group n = 6, bone lesions n = 1, bone marrow involvement n = 3, CNS involvement n = 1, soft tissue mass n = 1, CD3 n = 4, MDD n = 21.